News and Announcements

GSK highlights pipeline momentum with Ris‑Rez phase III success, Jideytro first‑line efficacy

By Iain Gilbert

Date: Monday 14 Sep 2026

(Sharecast News) - Drugmaker GSK reported two major advances in its oncology pipeline on Monday, as new data showed its B7‑H3 antibody‑drug conjugate Ris‑Rez delivered a significant survival benefit in relapsed small cell lung cancer, while registrational results for Jideytro supported a potential move into first‑line ROS1‑positive non‑small cell lung cancer.

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page